Suven Life Sciences Reaches Over 55% Enrollment within Three Months in Phase-2b Clinical Trial of Ropanicant for Major Depressive Disorder (MDD), being conducted in USA.

The company is making strong strides in the clinical development of Ropanicant, with the final patient expected to be enrolled by February 2026.

Hyderabad, India (27-Oct-2025) - Suven Life Sciences, a clinical-stage biopharmaceutical company focused on discovering and developing innovative treatments for Central Nervous System (CNS) disorders, announced today that its Phase-2b clinical trial of Ropanicant, a nicotinic α4β2 receptor antagonist for treating Major Depressive Disorder (MDD), has successfully reached over 55% of its enrollment target within three months from the study initiation. The trial is being conducted exclusively in the United States of America.

Key Highlights of the Ropanicant Phase-2b Study:

- **Study Design**: The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA for a treatment duration of six weeks. The study will evaluate the efficacy and safety of Ropanicant in patients with MDD, compared to placebo, in improving symptoms of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS). For more information about the Phase-2b study visit ClinicalTrials.gov. Identifier NCT06836063.
- **Enrollment Progress**: Within three months of study initiation, more than 55% of the targeted patient enrollment (108 patients enrolled out of 195 to be randomized) has been achieved. This rapid enrollment is indicative of the high level of interest among both patients and investigators.
- **Safety and Tolerability**: Safety data from the study are being monitored continuously, with no significant concerns observed to date.

Suven anticipates the Last Patient In (LPI) by February 2026. Topline data readout is expected by June 2026.

“The rapid progress in enrollment is a significant milestone for Suven Life Sciences, highlighting the growing interest in Ropanicant as a promising treatment for MDD. This achievement reflects both the substantial unmet medical need in managing this condition and the operational excellence of our clinical development team.” said Mr. Venkat Jasti, Chairman and Managing Director of Suven Life Sciences.

“We are pleased with the continued momentum of the study and are committed to maintaining this pace with the highest scientific standards. With its novel mechanism of action, we are confident that Ropanicant holds the potential to provide a valuable therapeutic option for patients with MDD. Our focus remains on advancing the program efficiently, and we look forward to presenting outcome of this trial by mid-2026” said Dr. Ramakrishna Nirogi, President and CSO of Suven Life Sciences.

About Ropanicant (SUVN-911): Ropanicant is a novel, selective a nicotinic α4β2 receptor antagonist in development for MDD. It has shown strong efficacy in animal models of depression and may address key limitations of current treatments, including rapid onset of action, reduced sexual dysfunction, and enhanced cognitive function. Non-clinical safety has been established through extensive pharmacology and toxicity studies (up to 9 months). In Phase-1 trials, Ropanicant was safe and well tolerated at the highest doses, with no significant effects from food or age. The Phase-2a trial demonstrated a favorable safety profile and significant improvements in depressive symptoms, as measured by the MADRS score. Suven fully owns Ropanicant's intellectual property rights.

About Suven Life Sciences: Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in CNS disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), Sleep disorders, Major depressive disorders (MDD), Parkinson's disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 5 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (Global Phase-3 study ongoing); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study for EDS completed; Phase-2 study for Cataplexy and pivotal Phase-3 study for EDS are in planning); Ropanicant (SUVN-911) for MDD (Open-label Phase-2a study completed; Double blind randomized Placebo controlled Phase-2b study ongoing); Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 study in planning), SUVN-I6107 for cognitive disorders (Phase-1 study ongoing). In addition to these clinical assets, we have 7 projects in research pipeline across multiple indications. Suven owns all intellectual property rights for its assets in all major markets.

For more information, please visit our website http://www.suven.com

Risk Statement: *Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*